Page last updated: 2024-10-30

letrozole and Stunted Growth

letrozole has been researched along with Stunted Growth in 22 studies

Research Excerpts

ExcerptRelevanceReference
"Letrozole was superior to placebo [mean difference (MD) 4."2.82Efficacy and Safety of Letrozole in the Management of Constitutional Delay in Growth and Puberty: A Systematic Review and Meta-analysis ( Dutta, D; Sharma, M; Singla, R; Surana, V, 2022)
"Letrozole was more potent in hormonal manipulation than anastrozole."2.79Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. ( Kumar, RB; Neely, EK; Payne, SL; Ranadive, SA; Suchet, DI, 2014)
"In letrozole-treated boys, the concentrations of the bone resorption marker urine aminoterminal telopeptide of type I collagen initially increased and thereafter slowly declined while the concentrations of the bone formation markers serum aminoterminal propeptide of type I collagen and serum alkaline phosphatase remained unchanged or slightly increased, respectively."2.74Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. ( Dunkel, L; Hero, M; Kröger, H; Mäkitie, O; Nousiainen, E; Toiviainen-Salo, S, 2009)
"Letrozole treatment caused sustained reduction in bone strength and alteration in skeletal geometry, lowering of IGF1 levels, inhibition of growth resulting in significantly lower weight and length of treated animals and development of focal prostatic hyperplasia."1.36Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia. ( Azar, WJ; Bajpai, A; McPherson, SJ; Risbridger, GP; Russo, VC; Simm, PJ; Wark, JD; Werther, GA, 2010)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (31.82)29.6817
2010's11 (50.00)24.3611
2020's4 (18.18)2.80

Authors

AuthorsStudies
Dutta, D1
Singla, R1
Surana, V1
Sharma, M1
Likki, SR1
Allen, HF1
Knee, A1
Tonyushkina, KN1
Cui, YP1
Wang, XL1
Rohani, F1
Asadi, R1
Mirboluk, AA1
Soheilipour, F1
Kohva, E1
Varimo, T3
Huopio, H1
Tenhola, S1
Voutilainen, R1
Toppari, J1
Miettinen, PJ3
Vaaralahti, K4
Viinamäki, J1
Backman, JT1
Hero, M8
Raivio, T4
Wang, Y1
Neely, EK1
Kumar, RB1
Payne, SL1
Ranadive, SA1
Suchet, DI1
Dunkel, L7
Mäkitie, O2
Kröger, H1
Nousiainen, E1
Toiviainen-Salo, S2
Kumar, KV1
Jayaraman, M1
Verma, A1
Modi, KD1
Wickman, S1
Maury, S1
Luotoniemi, E1
Service, E1
Salehpour, S1
Alipour, P1
Razzaghy-Azar, M1
Ardeshirpour, L1
Shamshiri, A1
Monfared, MF1
Gharib, A1
Bajpai, A1
Simm, PJ1
McPherson, SJ1
Russo, VC1
Azar, WJ1
Wark, JD1
Risbridger, GP1
Werther, GA1
Tommiska, J1
Laitinen, EM1
Sipilä, I1
Puhakka, L1
Krebs, A1
Moske-Eick, O1
Doerfer, J1
Roemer-Pergher, C1
van der Werf-Grohmann, N1
Schwab, KO1
Zhou, P1
Shah, B1
Prasad, K1
David, R1
Karmazin, A1
Moore, WV2
Popovic, J2
Jacobson, JD2
Norjavaara, E1
Cernich, J1
Chagin, AS1
Sävendahl, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment[NCT01797718]Phase 2/Phase 335 participants (Actual)Interventional2013-10-31Completed
Randomization to Letrozole vs. Anastrozole in Short Pubertal Males[NCT02137538]Phase 479 participants (Actual)Interventional2009-11-18Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Predicted Adult Height at Year 3

"Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.~Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age)." (NCT02137538)
Timeframe: Year 3

Interventioncm (Mean)
Letrozole167.8
Anastrozole169.4

Androstenedione

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionng/dL (Mean)
BaselineYear 3
Anastrozole37.477.9
Letrozole35.379.9

Dihydrotestosterone

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionng/dL (Mean)
BaselineYear 3
Anastrozole19.144.1
Letrozole22.565.0

Estradiol

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionpg/mL (Mean)
BaselineYear 3
Anastrozole4.76.2
Letrozole4.92.7

Estrone

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionpg/mL (Mean)
BaselineYear 3
Anastrozole8.03.5
Letrozole8.72.7

Follicle Stimulating Hormone

(NCT02137538)
Timeframe: Baseline, year 3

,
InterventionmIU/mL (Mean)
BaselineYear 3
Anastrozole2.54.5
Letrozole3.36.6

Inhibin B

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionpg/mL (Mean)
BaselineYear 3
Anastrozole217.0262.1
Letrozole203.4257.6

Insulin-like Growth Factor Type 1

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionng/mL (Mean)
BaselineYear 3
Anastrozole306.9298.7
Letrozole306.2226.1

Luteinizing Hormone

(NCT02137538)
Timeframe: Baseline, year 3

,
InterventionmIU/mL (Mean)
BaselineYear 3
Anastrozole1.83.4
Letrozole2.34.7

Number of Adverse Events Related to Acne or Bone Fracture

(NCT02137538)
Timeframe: 3 years

,
Interventionevents (Number)
AcneFracture
Anastrozole35
Letrozole33

Serum Testosterone

(NCT02137538)
Timeframe: Baseline, year 3

,
Interventionng/dL (Mean)
BaselineYear 3
Anastrozole162.1680.1
Letrozole213.1882.3

Reviews

2 reviews available for letrozole and Stunted Growth

ArticleYear
Efficacy and Safety of Letrozole in the Management of Constitutional Delay in Growth and Puberty: A Systematic Review and Meta-analysis
    Journal of clinical research in pediatric endocrinology, 2022, 06-07, Volume: 14, Issue:2

    Topics: Body Height; Child; Growth Disorders; Humans; Letrozole; Luteinizing Hormone; Puberty; Puberty, Dela

2022
Use of aromatase inhibitors in children with short stature.
    Pediatric endocrinology reviews : PER, 2004, Volume: 2, Issue:1

    Topics: Adult; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Body Height; Child; Estrogens; Fema

2004

Trials

11 trials available for letrozole and Stunted Growth

ArticleYear
Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone.
    Human reproduction (Oxford, England), 2020, 02-29, Volume: 35, Issue:2

    Topics: Adolescent; Anti-Mullerian Hormone; Biomarkers; Child; Female; Finland; Growth Disorders; Humans; Hy

2020
Circulating miR-30b levels increase during male puberty.
    European journal of endocrinology, 2021, Volume: 184, Issue:5

    Topics: Adolescent; Drug Therapy, Combination; Gonads; Growth Disorders; Hormone Replacement Therapy; Humans

2021
Letrozole vs anastrozole for height augmentation in short pubertal males: first year data.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:11

    Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Body Height; Child; Estradiol; Growth Disorders; Huma

2014
Circulating makorin ring finger protein 3 levels decline in boys before the clinical onset of puberty.
    European journal of endocrinology, 2016, Volume: 174, Issue:6

    Topics: Adolescent; Aromatase Inhibitors; Child; Double-Blind Method; Growth Disorders; Humans; Letrozole; M

2016
Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature.
    Hormone research, 2009, Volume: 71, Issue:5

    Topics: Absorptiometry, Photon; Adolescent; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Develop

2009
Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2010, Volume: 25, Issue:7

    Topics: Adolescent; Aromatase Inhibitors; Child; Growth Disorders; Humans; Letrozole; Magnetic Resonance Ima

2010
Cognitive effects of aromatase inhibitor therapy in peripubertal boys.
    European journal of endocrinology, 2010, Volume: 163, Issue:1

    Topics: Adolescent; Aromatase Inhibitors; Child; Cognition; Double-Blind Method; Growth Disorders; Humans; L

2010
A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature.
    Hormone research in paediatrics, 2010, Volume: 74, Issue:6

    Topics: Adolescent; Androgens; Aromatase Inhibitors; Body Height; Bone Density; Cholesterol; Double-Blind Me

2010
Circulating antimüllerian hormone levels in boys decline during early puberty and correlate with inhibin B.
    Fertility and sterility, 2012, Volume: 97, Issue:5

    Topics: Adolescent; Anti-Mullerian Hormone; Aromatase Inhibitors; Biomarkers; Child; Cross-Sectional Studies

2012
The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function.
    Journal of pediatric endocrinology & metabolism : JPEM, 2005, Volume: 18, Issue:3

    Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Aromatase Inhibitors; Body Height; Bone and

2005
Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:12

    Topics: Absorptiometry, Photon; Adolescent; Aromatase Inhibitors; Body Height; Bone Density; Child; Double-B

2005

Other Studies

9 other studies available for letrozole and Stunted Growth

ArticleYear
Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review.
    Journal of pediatric endocrinology & metabolism : JPEM, 2022, Oct-26, Volume: 35, Issue:10

    Topics: Adult; Body Height; Growth Disorders; Growth Hormone; Human Growth Hormone; Humans; Letrozole; Male;

2022
[Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2019, Volume: 21, Issue:10

    Topics: Adolescent; Body Height; Dwarfism; Growth Disorders; Human Growth Hormone; Humans; Letrozole; Male;

2019
Letrozole Effect on Final Height of Patients with Constitutional Delay of Growth and Puberty.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2019, Volume: 73, Issue:5

    Topics: Adolescent; Aromatase Inhibitors; Body Height; Case-Control Studies; Follow-Up Studies; Growth Disor

2019
Letrozole as a booster therapy in growth hormone deficiency.
    Indian pediatrics, 2009, Volume: 46, Issue:7

    Topics: Adolescent; Aromatase Inhibitors; Growth Disorders; Growth Hormone; Humans; Letrozole; Male; Nitrile

2009
Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.
    The Journal of endocrinology, 2010, Volume: 207, Issue:1

    Topics: Animals; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Development; Child; Growth Disorde

2010
Off-label use of aromatase inhibitors to promote taller stature: is it safe.
    Hormone research in paediatrics, 2010, Volume: 74, Issue:6

    Topics: Adolescent; Aromatase Inhibitors; Body Height; Growth Disorders; Humans; Letrozole; Male; Nitriles;

2010
Marked increase of final height by long-term aromatase inhibition in a boy with idiopathic short stature.
    Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:5-6

    Topics: Adolescent; Aromatase; Aromatase Inhibitors; Body Height; Bone and Bones; Growth Disorders; Humans;

2012
Letrozole significantly improves growth potential in a pubertal boy with growth hormone deficiency.
    Pediatrics, 2005, Volume: 115, Issue:2

    Topics: Adolescent; Aromatase Inhibitors; Biomarkers; Bone Density; Drug Therapy, Combination; Growth Disord

2005
Oestrogen receptors and linear bone growth.
    Acta paediatrica (Oslo, Norway : 1992), 2007, Volume: 96, Issue:9

    Topics: Animals; Anthropometry; Aromatase Inhibitors; Bone Development; Child; Estrogen Receptor beta; Estro

2007